Baird downgraded Leap Therapeutics (LPTX) to Neutral from Outperform with a price target of $1.25, down from $9, after after the company announced results from Phase 2 trials of sirexatamab in colorectal cancer and gastric cancer. The response rate data provides “some good support” that sirexatamab has activity in cancers, but the “mixed and inconclusive” survival data to date, along with a “worsened” financial overhang after the stock reaction, leave Baird questioning the viability of Leap’s path ahead, the analyst tells investors in a research note.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LPTX:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue